Provided by Tiger Trade Technology Pte. Ltd.

AQR Capital Holdings

2,718.82
+9.830.36%
Number of Gainers:56
Number of Losers:41
Number of Flat:1
PE:- -
High:2,727.96
Open:2,708.94
Low:2,708.43
Close:2,708.99
Volume:1.01B
Turnover:207.60B
Market Cap:49.73T
Float Cap:46.27T

Loading ...

Nasdaq Extends Gains to 1%, S&P 500 Currently Up 0.58%

Deep News
·
Sep 30

Rich Goldman Narrows Annual Loss Despite Ongoing Loan Impairments

TIPRANKS
·
Sep 30

Option traders moderately bearish in Moderna with shares down 6.7%

TIPRANKS
·
Sep 30

Anthropic's Potential $2 Trillion-Plus IPO Supports Robust AI Infrastructure Spending, Wedbush Says

MT Newswires Live
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Micron Earnings Prediction Market Preview: Can the AI Memory Boom Keep Running?

Benzinga Earnings
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Micron Technology (MU US) FQ4-26 Results: Beat on Every Line, FQ1 Guide ~8% Above the Street

Smartkarma
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Moody’s downgrades Hormel Foods to A3; outlook stable

TIPRANKS
·
Sep 30

Amazon call volume above normal and directionally bullish

TIPRANKS
·
Sep 30

Market Chatter: FedEx Places Order for 2,000 Harbinger Electric Trucks in $300 Million Deal

MT Newswires Live
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

US Stocks-Wall St Climbs as Cooling Inflation Tempers Fed Rate-Hike Concerns

Reuters
·
Sep 30

Gulf Oil Exports are Basically Back to Normal. Why are Prices Still so High?

Dow Jones
·
Sep 30

Mastercard Adds Trust, Intelligence Services to Agentic Payments Program

MT Newswires Live
·
Sep 30